Insulin and the Eyes: Systemic Benefits, Experimental Uses, and Risks
Insulin affects the eye primarily through systemic glycemic control; direct intraocular injection is experimental (not standard).
Systemic Effects (Diabetes Context)
- Hypoglycemia: Blurred vision, diplopia, confusion – reversible with glucose.
- Chronic Hyperglycemia → Retinopathy: Microaneurysms, hemorrhages, exudates, neovascularization (PDR), macular edema (DME). Insulin therapy reduces progression (DCCT/UKPDS).
- Cataracts: Diabetes increases risk (sorbitol pathway); insulin mitigates by improving control. No direct causation.
- Glaucoma: Diabetes increases risk (neovascular, open‑angle); insulin not causative.
Intravitreal Insulin (Experimental)
Studied for DME (insulin receptors on retinal cells). Not approved; risks: hypoglycemia, fibrosis, endophthalmitis.
Clinical Bottom Line
Proper insulin therapy protects the eye by achieving glycemic targets. Ocular side effects stem from dysglycemia, not insulin itself. Regular dilated eye exams are essential.
Eye & Vision Disorders - Related Articles
- Effective Treatments for Dry Eye: Relief & Management
- Choosing the Right Eyeglass Lenses: A Comprehensive Guide
- Binocular Prisms: Understanding and Uses in Vision Therapy
- Eye Floaters: Understanding Causes, Management & Potential Treatments
- Pilot Vision Standards: Myopia Is Not Disqualifying If Correctable
- Prosthetic Eyes: Understanding Artificial Eyes and Their Benefits
- Free Online Color Blindness Test | Color Vision Testing
